How much does fotantinib/fotantinib cost per box of medicine?

Fostamatinib has not yet been officially marketed in mainland China, so its price information cannot be found in the domestic drug catalog and cannot be included in the current medical insurance policy system. However, this drug has been approved by regulatory authorities in developed countries such as Europe and the United States, especially in the United States and Germany. It is mainly used to treat chronic immune thrombocytopenia (ITP) and other related conditions. Taking the German market as an example, the original drug of fotantinib is called Tavalisse. The most common specifications currently on the market are 100 mg 60 tablets and 150 mg 60 tablets. Taking 100mg*60 tablets as an example, its international market price is usually between RMB 20,000 and RMB 40,000. The price is specifically affected by factors such as exchange rate fluctuations, channel differences, and delivery methods.

There are no generic versions of Fotantinib in overseas markets, so the current price is basically determined by the original drug, and there is no price competition mechanism. In addition, the drug is used by a relatively specific population, mostly focusing on ITP patients who do not respond to or relapse to standard treatment. If some domestic patients need medicine, they often obtain the medicine through cross-border medical treatment or overseas purchasing platforms. However, there are large differences in the legality and drug quality assurance of such channels. Although some cross-border e-commerce companies or international hospitals provide genuine drug sources, prices are often higher due to the complexity of drug transportation, storage, customs clearance and other links, and the lack of medical regulatory support puts patients at considerable risk.

From the perspective of medical insurance policies, if fotantinib is launched in China in the future, whether it can be included in the national medical insurance drug catalog will be affected by many aspects. Judging from the current international usage, fotantinib is mostly used for patients with refractory or relapsed ITP, and its applicable population is relatively small. However, because it represents a new trend in targeted therapy, if the price reduction mechanism can be negotiated, it may enter the scope of medical insurance coverage for specific groups of people.

Reference materials:https://go.drugbank.com/drugs/DB12010